Management of Hyperglycaemia in Type 2 Diabetes

Management of hyperglycaemia in type 2 diabetes,2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of  Diabetes (EASD)

Melanie  j. Davies   . David A. D'Alessio    . Judith Fradkin   . Walter N.  Chantal Mathieu       .Geltrude Mingrone     . Peter Rossing      . Apostolos Tsapas     . Deborah  J. Wexler   .John B.Buse

Abstract

The American Diabetes Assoaciation and the European  for the Study of Diabetes convened a panel to update the prior position statements ,published in 2012, onb the management of  type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations.These include additional focus on lifestyl management and diabetes selfmanagement education and support. For those with obesity, efforts targeting weight loss,including lifestyle, medication and surgical interventions, are recommended. With regards to medication management , for patients with clinical cardiovascular  disease, a sodiumglucose contranssporter-2 (SGLT2) inhibitor or a glucagon -like peptide -1 (GLP-1)  receptor agonist with proven cardiovascular disease, an SGLT2  reccommendede. For patients with  chronic kidney disease or elinical heart failure and atherosclerotic cardiovascular disease, aan SGLT2İNHİBİTOR with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.